Vistagen Therapeutics (VTGN) Invested Capital (2011 - 2020)
Vistagen Therapeutics (VTGN) posted Invested Capital of $98400.0 for Q4 2020, down 72.09% sequentially from $352600.0 in Q3 2020, and up 39.57% YoY from $70500.0 in Q1 2020.
Vistagen Therapeutics (VTGN) Invested Capital (2011 - 2020) Analysis & Trends
Vistagen Therapeutics has reported Invested Capital for 9 years, with the latest figure at $98400.0 in Q4 2020.
- Quarterly Invested Capital rose 39.57% year-over-year to $98400.0 in Q4 2020, while the trailing twelve-month figure through Sep 2021 was $98400.0 (down 89.17% YoY) and the FY2020 annual result came in at $56500.0, down 1.4% from the prior year.
- Invested Capital eased to $98400.0 in Q4 2020 per VTGN's latest filing, from $352600.0 in the prior quarter.
- Over five years, Invested Capital peaked at $428900.0 in Q2 2020 and troughed at $35800.0 in Q4 2016.
- A 5-year average of $128788.9 and a median of $84450.0 in 2019 frame the typical range for Invested Capital.
- The sharpest annual moves came in 2018 and 2020: Invested Capital decreased 1.64% in 2018, then soared 121.34% in 2020.
- Over 5 years, Invested Capital stood at $35800.0 in 2016, then grew by 22.07% to $43700.0 in 2017, then rose by 12.36% to $49100.0 in 2018, then surged by 43.58% to $70500.0 in 2019, then soared by 39.57% to $98400.0 in 2020.
- According to Business Quant data, Invested Capital over the past three periods registered $98400.0, $352600.0, and $428900.0 for Q4 2020, Q3 2020, and Q2 2020 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Invested Cap. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 37.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 190.90 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 1.45 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 380.00 Mn |
| 10 | Vistagen Therapeutics | 10.49 Mn | 10.49 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2020 | 98,400.00 |
| Sep 30, 2020 | 352,600.00 |
| Jun 30, 2020 | 428,900.00 |
| Mar 31, 2020 | 56,500.00 |
| Dec 31, 2019 | 70,500.00 |
| Sep 30, 2019 | 159,300.00 |
| Jun 30, 2019 | 246,400.00 |
| Mar 31, 2019 | 57,300.00 |
| Dec 31, 2018 | 49,100.00 |
| Sep 30, 2018 | 115,600.00 |
| Jun 30, 2018 | 181,100.00 |
| Mar 31, 2018 | 53,900.00 |
| Dec 31, 2017 | 43,700.00 |
| Sep 30, 2017 | 105,200.00 |
| Jun 30, 2017 | 165,500.00 |
| Mar 31, 2017 | 54,800.00 |
| Dec 31, 2016 | 35,800.00 |
| Mar 31, 2016 | 43,600.00 |
| Dec 31, 2014 | 4.30 Mn |
| Mar 31, 2014 | 3,600.00 |